Hippocampal Volume in Psychiatric Diagnoses: Should Psychiatry Biomarker Research Account for Comorbidities?
alcohol use disorder
amygdala volume
borderline personality disorder
brain morphometry
comorbidity
hippocampus volume
major depressive disorder
posttraumatic stress disorder
psychiatry research
Journal
Chronic stress (Thousand Oaks, Calif.)
ISSN: 2470-5470
Titre abrégé: Chronic Stress (Thousand Oaks)
Pays: United States
ID NLM: 101701229
Informations de publication
Date de publication:
Historique:
received:
02
01
2020
accepted:
24
01
2020
entrez:
23
5
2020
pubmed:
23
5
2020
medline:
23
5
2020
Statut:
epublish
Résumé
Many research papers claim that patients with specific psychiatric disorders (major depressive disorder, posttraumatic stress disorder, borderline personality disorder, alcohol use disorder, and others) have smaller hippocampi, but most of those reports compared patients to healthy controls. We hypothesized that if psychiatrically matched controls (psychiatric control, matched for demographics and psychiatric comorbidities) were used, much of the biomarker literature in psychiatric research would not replicate. We used hippocampus and amygdala volume only as examples, as these are very commonly replicated results in psychiatry biomarker research. We propose that psychiatry biomarker research could benefit from using psychiatric controls, as the use of healthy controls results in data that are not disorder-specific. Hippocampus/amygdala volumes were compared between major depressive disorder, sex-/age-/race-matched healthy control, and psychiatric control (N = 126/group). Similar comparisons were performed for posttraumatic stress disorder (N = 67), borderline personality disorder (N = 111), and alcohol use disorder (N = 136). Major depressive disorder patients had smaller left (p = 8.79 × 10 When psychiatric controls were used, there was no difference in hippocampal or amygdalar volume between any of the diagnoses studied and controls. This strategy (keeping all possible relevant variables matched between experimental groups) has been used to advance science for hundreds of years, and we propose should also be used in biomarker psychiatry research.
Sections du résumé
BACKGROUND
BACKGROUND
Many research papers claim that patients with specific psychiatric disorders (major depressive disorder, posttraumatic stress disorder, borderline personality disorder, alcohol use disorder, and others) have smaller hippocampi, but most of those reports compared patients to healthy controls. We hypothesized that if psychiatrically matched controls (psychiatric control, matched for demographics and psychiatric comorbidities) were used, much of the biomarker literature in psychiatric research would not replicate. We used hippocampus and amygdala volume only as examples, as these are very commonly replicated results in psychiatry biomarker research. We propose that psychiatry biomarker research could benefit from using psychiatric controls, as the use of healthy controls results in data that are not disorder-specific.
METHOD
METHODS
Hippocampus/amygdala volumes were compared between major depressive disorder, sex-/age-/race-matched healthy control, and psychiatric control (N = 126/group). Similar comparisons were performed for posttraumatic stress disorder (N = 67), borderline personality disorder (N = 111), and alcohol use disorder (N = 136).
RESULTS
RESULTS
Major depressive disorder patients had smaller left (p = 8.79 × 10
CONCLUSION
CONCLUSIONS
When psychiatric controls were used, there was no difference in hippocampal or amygdalar volume between any of the diagnoses studied and controls. This strategy (keeping all possible relevant variables matched between experimental groups) has been used to advance science for hundreds of years, and we propose should also be used in biomarker psychiatry research.
Identifiants
pubmed: 32440605
doi: 10.1177/2470547020906799
pii: 10.1177_2470547020906799
pmc: PMC7219869
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2470547020906799Subventions
Organisme : RRD VA
ID : I21 RX002588
Pays : United States
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Am J Psychiatry. 2010 Jul;167(7):748-51
pubmed: 20595427
Eur Psychiatry. 2014 Mar;29(3):125-33
pubmed: 23182846
Psychiatry Res. 2007 Feb 28;154(2):157-70
pubmed: 17306512
J Psychiatr Res. 2012 Apr;46(4):516-25
pubmed: 22336640
Am J Addict. 2017 Oct;26(7):751-759
pubmed: 28857330
Drug Alcohol Depend. 2014 Nov 1;144:170-7
pubmed: 25263262
J Neuropsychiatry Clin Neurosci. 2015;27(2):e170-1
pubmed: 25923873
Biol Psychiatry. 2003 Jul 15;54(2):163-71
pubmed: 12873806
Arch Gen Psychiatry. 2000 Dec;57(12):1115-22
pubmed: 11115325
Psychiatry Res. 2005 Jul 30;139(2):89-99
pubmed: 15967648
Biol Psychiatry. 2018 Feb 1;83(3):244-253
pubmed: 29217296
Lancet. 2013 Nov 9;382(9904):1575-86
pubmed: 23993280
Acta Psychiatr Scand. 2017 Jul;136(1):129-139
pubmed: 28369737
Biol Psychiatry. 2004 Sep 1;56(5):356-63
pubmed: 15336518
J Psychiatry Neurosci. 2013 Mar;38(2):129-37
pubmed: 22909445
Cogn Behav Neurol. 2003 Dec;16(4):219-24
pubmed: 14665821
Psychother Psychosom. 2006;75(2):122-32
pubmed: 16508348
J Psychiatry Neurosci. 2009 Jul;34(4):289-95
pubmed: 19568480
J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):610-4
pubmed: 17088334
Neuroreport. 2009 Oct 28;20(16):1402-6
pubmed: 19794316
PLoS One. 2018 Feb 21;13(2):e0191946
pubmed: 29466364
Biol Psychiatry. 2011 Mar 15;69(6):541-8
pubmed: 21094937
J Clin Psychiatry. 2008 Jul;69(7):1087-91
pubmed: 18572983
Am J Psychiatry. 2000 May;157(5):737-44
pubmed: 10784466
Biol Psychiatry. 2008 Aug 1;64(3):192-202
pubmed: 18374900
J Psychiatr Res. 2008 Jul;42(9):752-62
pubmed: 17892884
Neuroimage. 2008 Jul 1;41(3):1067-74
pubmed: 18424082
Alcohol Clin Exp Res. 2014 Mar;38(3):739-48
pubmed: 24483366
Psychiatry Res. 2003 Apr 1;122(3):193-8
pubmed: 12694893
Biol Psychiatry. 2002 Jul 15;52(2):119-25
pubmed: 12114003
Psychiatry Res. 2004 Jul 30;131(2):125-33
pubmed: 15313519
Neuroimage Clin. 2013 Jul 11;3:47-53
pubmed: 24179848
Mol Psychiatry. 2016 Jun;21(6):806-12
pubmed: 26122586
J Affect Disord. 2016 Aug;200:266-74
pubmed: 27155069
Psychiatry Res. 2008 Jul 15;163(2):116-25
pubmed: 18395424
Metab Brain Dis. 2014 Jun;29(2):311-21
pubmed: 24496784
Neurosci Biobehav Rev. 2016 Jul;66:92-103
pubmed: 27108216
Biol Psychiatry. 2005 Jan 15;57(2):173-82
pubmed: 15652877
Psychiatry Res. 2015 Mar 30;231(3):218-26
pubmed: 25624067
Psychiatry Res. 2011 May 31;192(2):84-90
pubmed: 21498053
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
J Trauma Stress. 1998 Jul;11(3):521-42
pubmed: 9690191
Biol Psychiatry. 1996 Dec 1;40(11):1091-9
pubmed: 8931911
Am J Psychiatry. 2008 Sep;165(9):1179-84
pubmed: 18593776
Neuropharmacology. 2015 May;92:63-8
pubmed: 25592214
Can J Psychiatry. 2006 Jun;51(7):431-7
pubmed: 16838824
Biol Psychiatry. 1997 Jan 1;41(1):23-32
pubmed: 8988792
J Psychiatry Neurosci. 2009 Sep;34(5):383-8
pubmed: 19721849
Biol Psychiatry. 2006 Aug 1;60(3):302-10
pubmed: 16476409
Addict Biol. 2017 May;22(3):864-872
pubmed: 26771165